

## Behandlung der arteriellen Hypertonie durch renale Denervation

## Traitement de l'hypertension artérielle résistante par la dénervation rénale

### Literatur / Références

1. Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. *Hypertension*. 2011;57:1076–1080.
2. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, Oliveras et al. Clinical features of 8295 Patients with resistant hypertension classified on the basis of ambulatory BP monitoring. *Hypertension*. 2011;57:898–902.
3. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. *Circulation*. 2012;125(13):1635–1642.
4. DiBona GF, Kopp UC. Neural control of renal function. *Physiological reviews*. 1997; 77(1):75–197
5. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. *NEJM*. 2009; 36(9): 932–934
6. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. *Lancet*. 2009; 373(9671): 1275–1281.
7. Symplicity HTNI. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. *Hypertension*. 2011;57(5):911–7.
8. Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. *Lancet*. 2010;376(9756):1903–9.
9. Kandzari DE, Bhatt DL, Sobotka PA, et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPPLICITY HTN-3 Trial. *Clin Cardiol*. 2012;35(9):528–535
10. Esler MD, Krum H, Schlaich M, Schmieder RE, Böhm M, Sobotka PA, et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. *Circulation*. 2012;126(25):2976–82.
11. Gosain P, Garimella PS, Hart PD, Agarwal R. Renal sympathetic denervation for treatment of resistant hypertension: a systematic review. *Journal of Clinical Hypertension*. 2013;15(1):75–84.
12. Persu A, Jin Y, Azizi M, Baelen M, Volz S, Elvan A, et al. Blood pressure changes after renal denervation at 10 European expert centers. *J Hum Hypertens*. 2013.
13. Mahfoud F, Ukena C, Schmieder RE, Cremers B, Rump LC, Vonend O, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. *Circulation* 2013;128(2):132–40.
14. Witkowski A, Prejbisz A, Florczak E, Kądziała J, Śliwiński P, Bielen P, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. *Hypertension*. 2011;58(4):559–65.
15. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. *Circulation*. 2011;123(18):1940–6.
16. Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Böhm M, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. *J Am Col of Cardiology* 2012;59(10):901–9.
17. Brandt MC, Reda S, Mahfoud F, Lenski M, Böhm M, Hoppe UC. Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension. *J Am Col of Cardiology*. 2012; 60(19): 1956–65.
18. Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA, Sobotka PA, Böhm M, Cremers B, Esler MD, Schlaich MP. Renal denervation in moderate to severe CKD. *J Am Soc Nephrol*. 2012; 23(7):1250–7.
19. Kaltenbach B, Id D, Franke JC, Sievert H, Hennersdorf M, Maier J, et al. Renal Artery Stenosis After Renal Sympathetic Denervation. *Journal of the American College of Cardiology*. 2012;60(25):2694–5.
20. Burnier M, Wuerzner G, Struijker-Boudier H, Urquhart J. Measuring, analyzing, and managing drug adherence in resistant hypertension. *Hypertension*. 2013; 62(2): 218–25
21. Savard S, Frank M, Bobrie G, Plouin PF, Sapoval M, Azizi M. Eligibility for renal denervation in patients with resistant hypertension: when enthusiasm meets reality in real-life patients. *J Am Col of Cardiology*. 2012; 60(23):2422–4.
22. Verloop WL, Vink EE, Voskuil M, Vonken EJ, Rookmaaker MB, Bots ML, et al. Eligibility for percutaneous renal denervation: the importance of a systematic screening. *Journal of hypertension*. 2013 a head of print.
23. Persu A, Jin Y, Baelen M, Schmidt B, et al. Proportion of patients eligible for renal denervation and reasons of non-eligibility: a European perspective. *Annales de Cardiologie et Angéiologie* 2013, 62: 3 (abstract)
24. Wuerzner G, Muller O, Erne P, Sudano I et al. Trans-Catheter Renal Denervation for the Treatment of Resistant Arterial Hypertension: the Swiss expert consensus. *Swiss Medical Weekly*, 2013; in press
25. Mancia G, Fagard R, Narkiewicz K, Redon J, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens* 2013; 31:1281–1357